How is continuous crystallization different from batch crystallization for pharmaceutical development?

Continuous crystallization operates at steady state, offering consistent product quality, reduced batch-to-batch variability, and higher throughput per vessel volume. The control strategy must address residence time distribution, supersaturation dynamics, and polymorph stability under continuous flow, which differ from batch cooling or antisolvent profiles. Our workflow accounts for these differences using mechanistic models and PAT.

What types of crystallizers do you support?

We support Mixed Suspension Mixed Product Removal (MSMPR) and Oscillatory Baffled Crystallizers (OBC), the two most common continuous designs for API manufacture. The selection depends on compound properties, solid handling, and required throughput. Each is modeled and sized to fit your process.

How do you ensure the metastable polymorph does not convert during continuous operation?

Metastable polymorph control is achieved by maintaining supersaturation within the form's metastable zone, using optimized seeding, and controlling temperature and anti-solvent addition profiles. In-line PAT (Raman, FBRM) monitors form conversion in real time, allowing feedback adjustments during development.

What analytical material is required to start a project?

Typically we require a few hundred milligrams of your compound for initial solubility, metastable zone width, and polymorph screening experiments. The exact amount is scoped per project depending on the number of conditions and crystallizer volume. Our service team will discuss material requirements during consultation.

Can your process be integrated with downstream continuous filtration and drying?

Our focus is on the crystallization step itself, but we design the slurry outlet conditions (temperature, solids concentration) to be compatible with downstream continuous filtration and drying operations commonly used in end-to-end continuous manufacturing. Coordination with downstream unit operations can be included in the project scope.

How do you handle regulatory aspects of the developed continuous process?

Our deliverables include the design space description, control strategy, and process understanding documentation that support regulatory submissions (IND, NDA). We do not provide regulatory filing services but supply the technical package your team needs to satisfy QbD and continuous manufacturing expectations.

Services

Online Inquiry

Name *

Email *

Subject *

Phone

Your Message

How Did You Hear About Us

Continuous Manufacturing Process Development for Crystallization

Continuous Crystallization

Transition from batch to continuous crystallization with confidence, backed by QbD-driven design space mapping and PAT integration.

Hybrid model-driven design space determination
Metastable polymorph control strategies
Real-time PAT integration for process monitoring
MSMPR or OBC crystallizer selection and sizing
Scalable from lab to commercial manufacturing

Develop Your Process

De-risking Continuous Crystallization for Pharmaceutical Manufacturing

Continuous crystallization offers consistent product quality and reduced cost, but successful implementation requires precise control over supersaturation, residence time, and mixing. Our service provides the hybrid modeling and experimental verification needed to consistently achieve your target crystal form and particle attributes through systematic process understanding and control.

Define CPPs and CQAs through systematic QbD
Design space mapped with mechanistic and data-driven models
PAT tools selected and validated for in-line monitoring
Metastable polymorph stability ensured across scale

Scalable

Predictive

PAT-Integrated

Our Methodology

A Hybrid Modeling & QbD Framework

We combine mechanistic understanding with experimental data to design a continuous crystallization process that delivers consistent quality attributes while minimizing development time and risk.

Model-Driven Process Design

Kinetic and thermodynamic models are built and validated with lab-scale data to simulate residence time distribution, supersaturation profiles, and polymorph conversion. These models guide equipment sizing and process parameter selection.

Mechanistic simulation for MSMPR and OBC configurations
CPP–CQA sensitivity analysis via hybrid models
Design space exploration with minimal experimental runs

Experimental Mapping & PAT Integration

Targeted experiments validate the design space and confirm polymorph control. Process analytical technology sensors (Raman, FBRM, turbidity) are deployed for real-time monitoring and feedback control.

Steady-state and transient runs to map operating window
In-line PAT for supersaturation and particle size tracking
Control strategy refined based on real-time data

Quality by Design

CPPs and CQAs are identified upfront to establish a design space that ensures reproducible crystal form and particle properties across scale.

Polymorph Control

Metastable forms are stabilized through optimized process conditions and seeding strategies, preventing unwanted conversion during continuous operation.

Scale-Up Support

Process modeling delivers equipment sizing recommendations and tech transfer documentation to accelerate pilot and commercial implementation.

What You Receive

Actionable Process Understanding & Documentation

Every project delivers a comprehensive data package that supports regulatory filing and seamless technology transfer.

Data Deliverables

Design space map with validated operating window
CPP–CQA correlation matrix and sensitivity analysis
Polymorph control strategy and stability data
PAT method selection and validation report

Reporting & Support

Final process development report with modeling details
Equipment sizing recommendations for scale-up
Technology transfer package (BPR, control strategy)
Consultation on regulatory filing strategy

Project Scope

Customizable to Your Molecule and Phase

The scope of each project is defined in collaboration with your team. Typical parameters are listed below and adapted to your specific development stage and compound properties.

Parameter	Typical Project Scope
Crystallizer Type	MSMPR or Oscillatory Baffled Crystallizer (OBC), selected based on compound characteristics
Crystal Form Target	Desired polymorph, hydrate, solvate, or co-crystal; stability against conversion routes
Process Mode	Antisolvent, cooling, or reactive crystallization; single- or multi-stage continuous
Modeling Approach	Hybrid mechanistic–data-driven models (e.g., population balance, CFD, ML surrogates)
PAT Tools	Raman spectroscopy, FBRM (focused beam reflectance measurement), turbidity, or ATR-FTIR as needed
Scale of Study	Lab (100-500 mL) through pilot (5-20 L) as scoped per project
Analytical Support	XRPD, DSC, TGA, HPLC, particle size distribution, microscopy
Documentation	Design space report, process description, control strategy, tech transfer package

Development Process

From Target to Validated Continuous Process

A structured, five-stage workflow that combines computational modeling with targeted experimentation to deliver a robust crystallization process.

Target Crystal Form & CQA Definition

Identify the desired polymorph or crystalline form and define critical quality attributes (e.g., particle size, morphology, purity). Establish baseline solid-state characterization.

CPP Identification & Design Space via QbD

Apply Quality by Design principles to map critical process parameters (temperature, feed rate, residence time, antisolvent ratio) to CQAs using design-of-experiments and mechanistic modeling.

Crystallizer Selection & Modeling

Select crystallizer type (MSMPR or OBC) based on compound properties and required throughput. Build population balance or hybrid models to simulate supersaturation and residence time distribution.

Process Simulation & Equipment Sizing

Run steady-state and dynamic simulations to define equipment geometry, mixing intensity, and heat transfer requirements. Optimize operating conditions for target yield and crystal attributes.

Experimental Validation & Control Strategy

Conduct laboratory-scale continuous runs to validate the design space. Deploy PAT sensors for real-time monitoring and refine the control strategy for consistent product quality.

Applications

Tailored Solutions for Pharmaceutical Challenges

Our continuous crystallization service addresses common solid-state development hurdles across API lifecycle stages.

Maintain Metastable Polymorph Stability in Continuous Mode

Metastable forms that offer superior bioavailability or manufacturability are notoriously difficult to scale. Our process design stabilizes the target form by controlling supersaturation, residence time, and seeding strategy, preventing conversion to more stable phases.

Seeding and anti-solvent addition profiles to favor metastable form
Real-time polymorph monitoring via Raman spectroscopy
Stability verification under steady-state continuous operation

Achieve Desired Crystal Size, Shape, and Flow Properties

Continuous crystallizers offer precise control over particle attributes through manipulation of mixing, residence time, and supersaturation. Our models predict the impact of CPPs on particle size distribution and morphology.

Target mean particle size and aspect ratio
Reduce fines or agglomeration through process tuning
Scale-up predictions for consistent powder handling

Purify API Through Selective Crystallization

Continuous crystallization can achieve higher purity by maintaining constant supersaturation and allowing selective inclusion or exclusion of impurities. Our approach integrates impurity fate studies into the design space.

Mechanistic modeling of impurity uptake
Optimize purge ratio and residence time for maximum rejection
PAT-based monitoring of impurity profiles

De-Risk Technology Transfer from Lab to Commercial

Hybrid models capture scale-dependent phenomena such as mixing and heat transfer, enabling reliable scale-up predictions. Our service provides equipment specifications, process control strategies, and a tech transfer package.

Computational fluid dynamics (CFD) for mixing and heat transfer
Pilot-scale experimental runs to validate model predictions
Comprehensive tech transfer report for regulatory submission

Frequently Asked Questions

Common Questions About Continuous Crystallization Development

We address typical concerns to help you evaluate this approach for your molecule.

Continuous crystallization operates at steady state, offering consistent product quality, reduced batch-to-batch variability, and higher throughput per vessel volume. The control strategy must address residence time distribution, supersaturation dynamics, and polymorph stability under continuous flow, which differ from batch cooling or antisolvent profiles. Our workflow accounts for these differences using mechanistic models and PAT.
We support Mixed Suspension Mixed Product Removal (MSMPR) and Oscillatory Baffled Crystallizers (OBC), the two most common continuous designs for API manufacture. The selection depends on compound properties, solid handling, and required throughput. Each is modeled and sized to fit your process.
Metastable polymorph control is achieved by maintaining supersaturation within the form's metastable zone, using optimized seeding, and controlling temperature and anti-solvent addition profiles. In-line PAT (Raman, FBRM) monitors form conversion in real time, allowing feedback adjustments during development.
Typically we require a few hundred milligrams of your compound for initial solubility, metastable zone width, and polymorph screening experiments. The exact amount is scoped per project depending on the number of conditions and crystallizer volume. Our service team will discuss material requirements during consultation.
Our focus is on the crystallization step itself, but we design the slurry outlet conditions (temperature, solids concentration) to be compatible with downstream continuous filtration and drying operations commonly used in end-to-end continuous manufacturing. Coordination with downstream unit operations can be included in the project scope.
Our deliverables include the design space description, control strategy, and process understanding documentation that support regulatory submissions (IND, NDA). We do not provide regulatory filing services but supply the technical package your team needs to satisfy QbD and continuous manufacturing expectations.

Scientific Literature

References

Zhao B, Zang H, Zhong L, et al. Review of the Application of PAT in the Pharmaceutical Continuous Crystallization Process. Current topics in medicinal chemistry. 2023;23(18):1699-1714. View on PubMed
Rajoub N, Gerard CJJ, Pantuso E, et al. A workflow for the development of template-assisted membrane crystallization downstream processing for monoclonal antibody purification. Nature protocols. 2023;18(10):2998-3049. View on PubMed

Please kindly note that our products and services are for research use only.